Researchers are developing a promising alternative to antibiotic treatment for infections caused byKlebsiella pneumoniaebacteria resistant to carbapenem antibiotics. The approach uses antibodies to target theK. pneumoniaeprotective capsule polysaccharide, allowing immune system cells called neutrophils to attack and kill the bacteria. The early stage,in vitroresearch was conducted by scientists at NIAID's Rocky Mountain Laboratories and the New Jersey Medical School-Rutgers University.
Klebsiellabacteria cause about 10 percent of all hospital-acquired infections in the United States. A carbapenem-resistantK. pneumoniaestrain known as multilocus sequence type 258 (ST258) is one of the antibiotic-resistant organisms labeled an urgent threat by the Centers for Disease Control and Prevention. ST258 is particularly concerning because it is resistant to most antibiotics. It is a significant cause of mortality among people with bloodstream infections.
研究人员首先确定细菌l capsule prevents immune system neutrophils from ingesting and killing ST258. They then extracted capsule from the two most abundant capsule types of ST258 and used them to generate antibodies in rabbits. In cell culture experiments they found that one of the antibodies enhanced the ability of neutrophils to ingest and kill bacteria. These results are a "proof of concept" for a potential immunotherapy approach for treatment of multidrug-resistantK. pneumoniaeinfections, the authors write.
Next up, the researchers will test the therapeutic concept in mice. They also will compare immunization with purified capsule polysaccharide as a preventive approach (active immunization) versus using capsule-specific antibodies as a therapy (passive immunization). Ultimately, they hope either antibody treatment alone or in combination with antibiotics could greatly improve care for people with multidrug-resistantK. pneumoniaeinfections.
Story Source:
Materialsprovided byNIH/National Institute of Allergy and Infectious Diseases.注:内容可以编辑为圣yle and length.
Journal Reference:
Cite This Page: